These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 30551517)

  • 1. Reactivation of p53 gene by MDM2 inhibitors: A novel therapy for cancer treatment.
    Gupta A; Shah K; Oza MJ; Behl T
    Biomed Pharmacother; 2019 Jan; 109():484-492. PubMed ID: 30551517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reactivation of p53 by inhibiting Mdm2 E3 ligase: a novel antitumor approach.
    Di J; Zhang Y; Zheng J
    Curr Cancer Drug Targets; 2011 Oct; 11(8):987-94. PubMed ID: 21762075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The regulation of MDM2 by multisite phosphorylation--opportunities for molecular-based intervention to target tumours?
    Meek DW; Hupp TR
    Semin Cancer Biol; 2010 Feb; 20(1):19-28. PubMed ID: 19897041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restoring p53 function in cancer: novel therapeutic approaches for applying the brakes to tumorigenesis.
    Di Cintio A; Di Gennaro E; Budillon A
    Recent Pat Anticancer Drug Discov; 2010 Jan; 5(1):1-13. PubMed ID: 19663772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TRIAD1 inhibits MDM2-mediated p53 ubiquitination and degradation.
    Bae S; Jung JH; Kim K; An IS; Kim SY; Lee JH; Park IC; Jin YW; Lee SJ; An S
    FEBS Lett; 2012 Sep; 586(19):3057-63. PubMed ID: 22819825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Escape, or Vanish: Control the Fate of p53 through MDM2-Mediated Ubiquitination.
    Wei J; Yang Y; Lu M; Xu L; Liu F; Yuan Z; Bao Q; Jiang Z; Xu X; Guo X; Zhang X; You Q; Sun H
    Anticancer Agents Med Chem; 2015; 16(2):174-89. PubMed ID: 26343143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The regulation of MDM2 oncogene and its impact on human cancers.
    Zhao Y; Yu H; Hu W
    Acta Biochim Biophys Sin (Shanghai); 2014 Mar; 46(3):180-9. PubMed ID: 24389645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance acquisition to MDM2 inhibitors.
    Cinatl J; Speidel D; Hardcastle I; Michaelis M
    Biochem Soc Trans; 2014 Aug; 42(4):752-7. PubMed ID: 25109953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.
    Tisato V; Voltan R; Gonelli A; Secchiero P; Zauli G
    J Hematol Oncol; 2017 Jul; 10(1):133. PubMed ID: 28673313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MDM2 oncogene as a novel target for human cancer therapy.
    Zhang ; Wang H
    Curr Pharm Des; 2000 Mar; 6(4):393-416. PubMed ID: 10788589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enigma negatively regulates p53 through MDM2 and promotes tumor cell survival in mice.
    Jung CR; Lim JH; Choi Y; Kim DG; Kang KJ; Noh SM; Im DS
    J Clin Invest; 2010 Dec; 120(12):4493-506. PubMed ID: 21060154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53-Mdm2 Interaction Inhibitors as Novel Nongenotoxic Anticancer Agents.
    Nayak SK; Khatik GL; Narang R; Monga V; Chopra HK
    Curr Cancer Drug Targets; 2018; 18(8):749-772. PubMed ID: 28669344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitors of MDM2 and MDMX: a structural perspective.
    Riedinger C; McDonnell JM
    Future Med Chem; 2009 Sep; 1(6):1075-94. PubMed ID: 21425995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MDM2 and MDM4: p53 regulators as targets in anticancer therapy.
    Toledo F; Wahl GM
    Int J Biochem Cell Biol; 2007; 39(7-8):1476-82. PubMed ID: 17499002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. UBTD1 induces cellular senescence through an UBTD1-Mdm2/p53 positive feedback loop.
    Zhang XW; Wang XF; Ni SJ; Qin W; Zhao LQ; Hua RX; Lu YW; Li J; Dimri GP; Guo WJ
    J Pathol; 2015 Mar; 235(4):656-67. PubMed ID: 25382750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of p53 in cancer drug resistance and targeted chemotherapy.
    Hientz K; Mohr A; Bhakta-Guha D; Efferth T
    Oncotarget; 2017 Jan; 8(5):8921-8946. PubMed ID: 27888811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular modeling approaches in the discovery of new drugs for anti-cancer therapy: the investigation of p53-MDM2 interaction and its inhibition by small molecules.
    Lauria A; Tutone M; Ippolito M; Pantano L; Almerico AM
    Curr Med Chem; 2010; 17(28):3142-54. PubMed ID: 20666726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patented inhibitors of p53-Mdm2 interaction (2006 - 2008).
    Weber L
    Expert Opin Ther Pat; 2010 Feb; 20(2):179-91. PubMed ID: 20100001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FOLICation: engineering approved drugs as potential p53-MDM2 interaction inhibitors for cancer therapy.
    Patil SP
    Med Hypotheses; 2013 Dec; 81(6):1104-7. PubMed ID: 24210632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential response between the p53 ubiquitin-protein ligases Pirh2 and MdM2 following DNA damage in human cancer cells.
    Duan W; Gao L; Wu X; Zhang Y; Otterson GA; Villalona-Calero MA
    Exp Cell Res; 2006 Oct; 312(17):3370-8. PubMed ID: 16934800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.